Integra LifeSciences Holdings Corp Stock News

PRINCETON, N.J., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Jan De Witte, president a

With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.

The CereLink overhang is largely removed, with Integra LifeSciences actively providing an intermediate solution to customers. Divisional strengths were the highlight in Q3 versus absolute numbers thro

Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.

Integra LifeSciences Holdings Corporation. (NASDAQ:IART ) Q3 2022 Earnings Conference Call October 26, 2022 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witt

Integra (IART) delivered earnings and revenue surprises of 19.44% and 1.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release third quarter 2022 financial re

Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.

Investors have punished Integra LifeSciences in FY22, most recently following the recall of its CereLink monitors. The market priced in the downside swiftly and with deep effect, helping shares find a

PRINCETON, N.J., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in

Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q2 2022 Earnings Conference Call July 27, 2022 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte -

Integra (IART) delivered earnings and revenue surprises of 2.50% and 0.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- ) Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release second quarter 2022 financial

Investors are optimistic about Integra's (IART) better-than-expected results and strong performance across several geographies.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.